

Company Overview

Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms.

Kane Biotech Announces First Quarter 2019 Financial Results, Extension of Loan and Insider Funding

May 22 2019, 4:15 PM EDT

Kane Biotech Announces First Quarter 2019 Earnings Conference Call and Business Update

May 16 2019, 4:15 PM EDT

Kane Biotech Provides Update on Exclusive License and Distribution Agreement with Dechra Veterinary Products

Apr 30 2019, 6:55 AM EDT

Stock Overview

Symbol	KNBIF
Exchange	OTCQB
Market Cap	5.47m
Last Price	\$0.0683
52-Week	\$0.04398 - \$0.0799

05/22/2019 10:24 AM EDT

Investor Relations

Edison Advisors
Joe Green
Senior Vice President, Investor Relations
1185 Avenue of the Americas
3rd Floor
New York, NY 10036
T: 646-653-7030
M: 917-575-7089
jgreen@edisongroup.com

Management Team

Marc Edwards

Director, Interim Chief Executive Officer

Ray Dupuis

Chief Financial Officer

Gordon Guay, Ph.D.

Chief Scientific Officer

Grant Humphrey

Vice President, Sales

Nanda Yakandawala

Senior Research Scientist

Wendy Nachtigall

Director, Marketing

Andrea Gordon

Director, Regulatory and Quality Control

Kane Biotech Inc.

162-196 Innovation Drive
Winnipeg, Manitoba R3T 2N2
Canada

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.